“Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 (TYK2) Inhibitor, in Patients With Moderate to Severe Scalp Psoriasis: The Association Between Patient-Reported and Clinician-Reported Outcomes at Week 16 in a Phase 3b 4 Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study (PSORIATYK SCALP)”. SKIN The Journal of Cutaneous Medicine 9, no. 2 (March 17, 2025): s528. Accessed June 25, 2025. https://skin.dermsquared.com/skin/article/view/3310.